A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementiaShifu Xiao, Raoli He, Jincai He et al.|Alzheimer s Research & Therapy|2021Cited by 200
Personalized risk prediction of symptomatic intracerebral hemorrhage after stroke thrombolysis using a machine-learning modelFeng Wang, Yuwu Zhao, Yuanhanqing Huang et al.|Therapeutic Advances in Neurological Disorders|2020Cited by 44
Reduction of HIP2 expression causes motor function impairment and increased vulnerability to dopaminergic degeneration in Parkinson’s disease modelsJinlin Su, Jin Xu, Pei Huang et al.|Cell Death and Disease|2018Cited by 30